Concerta vs. Metadate CD: Key Differences
Metadate CD provides superior symptom control during the school day (morning through early afternoon), while Concerta extends coverage into the early evening—choose Metadate CD when daytime school performance is the priority, and Concerta when late-day/evening coverage is needed. 1
Release Mechanism Differences
Metadate CD uses a beaded capsule system where 30% of the dose is delivered as immediate-release uncoated beads, with the remaining 70% released from polymer-coated beads 1. This creates higher early methylphenidate exposure.
Concerta employs an osmotic-release oral system (OROS) with only 22% immediate-release overcoat and 78% delivered through a laser-drilled orifice using osmotic pressure 2. The drug release rate increases over 6-7 hours due to a concentration gradient in its trilayer core 2.
Pharmacokinetic Profiles
The formulations produce distinctly different plasma concentration patterns 3:
- Metadate CD: Higher plasma concentrations at 1.5,3, and 4 hours post-dose; greater early exposure (AUC 0-4 and AUC 0-6) 3
- Concerta: Lower early peaks but higher concentrations at 8,10, and 12 hours; produces ascending plasma levels reaching peak at 6-10 hours 2
- Total exposure (AUC): Equivalent between formulations at comparable doses 3
Efficacy Across the Day
The COMACS study (2004) demonstrated four distinct efficacy patterns 1:
- Immediately post-dose: Neither formulation effective (placebo superiority)
- Morning (1.5-4.5 hours): Metadate CD superior to Concerta
- Afternoon (school day): Both formulations equivalent
- Early evening (12 hours): Concerta superior to Metadate CD
Critical finding: Metadate CD at lower doses (20-40 mg) provided equivalent morning symptom control to higher Concerta doses (36-54 mg), allowing reduced total daily methylphenidate exposure when morning coverage is the primary goal 4.
Duration of Action
- Metadate CD: Optimal for 6-8 hour coverage, strongest effects during typical school hours 5
- Concerta: Designed for 12-hour duration, maintains therapeutic levels into early evening 2
Clinical Decision Algorithm
Choose Metadate CD when:
- School-day symptom control is the primary concern (1.5-7.5 hours post-dose)
- Minimizing total daily methylphenidate exposure is desired
- Rapid morning onset is needed (peaks at 3 hours vs. 6-10 hours for Concerta) 6
Choose Concerta when:
- Extended coverage through homework/evening activities is required
- Late-day symptom control is problematic
- Once-daily dosing with evening efficacy is the priority 6
Dosing Equivalents
Near-equivalent daily doses 1:
- Metadate CD 20 mg ≈ Concerta 18 mg
- Metadate CD 40 mg ≈ Concerta 36 mg
- Metadate CD 60 mg ≈ Concerta 54 mg
However, these "equivalent" doses produce different temporal effects—the higher immediate-release component in Metadate CD (30% vs. 22%) creates superior early-day efficacy 1.
Safety Profile
Both formulations demonstrate comparable safety profiles with no significant differences in treatment-emergent adverse events, side effect ratings, or vital signs 1. Common adverse effects include decreased appetite, insomnia, and irritability 7.
Common Pitfall
Do not assume bioequivalent total daily doses produce equivalent symptom control throughout the day. The delivery mechanism fundamentally alters when peak efficacy occurs. Switching between formulations requires consideration of when symptom control is most needed, not just total milligram equivalence 3.
The older wax-matrix sustained-release formulations (Ritalin-SR, generic methylphenidate-SR) mentioned in guidelines 6 are inferior to both Metadate CD and Concerta, with delayed onset (90 minutes), lower peak concentrations, and reduced clinical efficacy compared to immediate-release methylphenidate given multiple times daily 6.